^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

GATA3 (GATA binding protein 3)

i
Other names: GATA3, HDR, GATA binding protein 3
1d
TRPS1 Expression Across the Spectrum of Paget Disease and Morphologic Mimics. (PubMed, Appl Immunohistochem Mol Morphol)
Among EMPD cases, perivulvar (n=10) and periscrotal (n=5) cases were consistently positive, whereas perianal lesions (n=10) showed no/weak expression. In summary, TRPS1 demonstrates universal expression in mammary PD of all ER/HER2 subgroups and in Toker cells, and corroborates recent reports regarding the utility of TRPS1 in site-of-origin studies.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • GATA3 (GATA binding protein 3) • TRPS1 (Transcriptional Repressor GATA Binding 1)
|
HER-2 negative
1d
Cytopathology of Sister Mary Joseph nodules: the Johns Hopkins experience. (PubMed, J Am Soc Cytopathol)
SMJN in current practice remains predominantly metastatic adenocarcinoma, most often gastrointestinal or gynecologic in origin. However, rare entities-including mesothelioma, melanoma, and lymphoma-underscore the need for a broad diagnostic differential. Fine-needle aspiration offers a rapid, minimally invasive diagnostic bridge and reinforces that the umbilicus remains a valuable clinical marker of an often occult malignancy.
Journal
|
WT1 (WT1 Transcription Factor) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
4d
Estrogen Receptor, GATA-3, TTF-1 and KRAS in Endometrial Carcinoma of No Specific Molecular Profile: Prognostic or Diagnostic Markers? (PubMed, Mod Pathol)
In conclusion, the different prognosis of ER-positive vs ER-negative NSMP endometrial carcinoma is not attributable to ER status itself, but rather to its strong correlation with histotype and other clinicopathological risk factors. Limited specificity of GATA3, TTF1 and KRAS warrant caution in their use as diagnostic markers of mesonephric-like carcinoma.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • POLE (DNA Polymerase Epsilon) • NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3)
|
KRAS mutation • ER positive • POLE mutation • ER negative
17d
Rectal metastasis in a patient with long-term breast cancer: a rare case report with literature review. (PubMed, Front Oncol)
This case underscores the importance of considering gastrointestinal metastasis in breast cancer patients with bowel symptoms, even years after initial treatment. We also review the literature regarding the literature on the diagnosis, treatment, and prognosis of breast cancer rectal metastasis.
Journal
|
CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
18d
Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.
Journal
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)
|
TP53 mutation
21d
A Histological Conundrum With a Distinctive Biochemical Marker: A Case Report of Primary Pulmonary Choriocarcinoma. (PubMed, Cureus)
This case illustrates the histopathological difficulties in diagnosing PPC and the utility of serum hCG measurement in the detection of PPC. Serum hCG measurement is useful as an initial investigation for possible PPC in patients with non-small cell lung tumors, which should be followed by immunohistochemical staining for markers of choriocarcinoma.
Journal
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NKX2-1 (NK2 Homeobox 1) • SALL4 (Spalt Like Transcription Factor 4) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin) • TCF4 (Transcription Factor 4)
24d
ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment. (PubMed, Curr Issues Mol Biol)
ADGRG6 functions as an oncogenic driver in PAAD, promoting tumor progression and fostering an immunosuppressive microenvironment via NF-κB/STAT6 signaling. These findings not only broaden the mechanistic understanding of ADGRG6 function but also suggest it as a promising target for therapeutic intervention in PAAD.
Journal
|
STAT6 (Signal transducer and activator of transcription 6) • ADGRG6 (Adhesion G Protein-Coupled Receptor G6) • GATA3 (GATA binding protein 3)
25d
Primary malignant Brenner tumor of the ovary: a case report. (PubMed, Front Oncol)
The patient was subsequently referred for adjuvant treatment. This case highlights the diagnostic challenge of MBT and underscores the critical role of immunohistochemistry (positive for GATA3 and p63, negative for Pax-8) in confirming the diagnosis and distinguishing MBT from its histological mimics.
Journal
|
TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
25d
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • CRP (C-reactive protein)
|
methotrexate
25d
The FOXC2-LAMA4 Axis Orchestrates Vasculogenic Mimicry and Immunosuppressive Niche Formation to Drive Metastatic Cascade in Renal Cell Carcinoma. (PubMed, Adv Sci (Weinh))
Disruption of LAMA4-ITGA6 binding substantially attenuated FOXC2-LAMA4-mediated metastatic burden. These results reveal a novel mechanism by which FOXC2+ tumor cells promote metastasis in advanced ccRCC and further establish the therapeutic potential of targeting FOXC2-LAMA4 in blocking the metastatic cascade of ccRCC.
Journal
|
GATA3 (GATA binding protein 3) • ITGA6 (Integrin, alpha 6) • FOXC2 (Forkhead Box C2)
27d
Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
While the panel showed promising performance for distinguishing MRD-positive from MRD-negative samples, the limited MRD-positive cohort size (n = 11) indicates that validation in larger MRD-focused studies is required before clinical implementation for treatment monitoring. This dPCR-based platform provides accessible, quantitative detection without requiring knowledge of clonal shifts or specific genomic landscape, offering potential advantages for resource-limited settings such as those represented in our Mexican pediatric cohort.
Journal
|
PTK7 (Protein Tyrosine Kinase 7) • ICOSLG (Inducible T Cell Costimulator Ligand) • GATA3 (GATA binding protein 3) • SNAI1 (Snail Family Transcriptional Repressor 1)
27d
Late Cervical Recurrence of Invasive Lobular Carcinoma Ten Years After Primary Breast Cancer: A Case Report and Review of the Literature. (PubMed, Healthcare (Basel))
The patient began systemic therapy with ribociclib plus letrozole, achieving radiologic improvement of the cervical lesion and abdominal disease. This case highlights the ability of ILC to recur after long latency and to metastasize to unusual gynecologic sites such as the cervix. We also review the literature on cervical recurrence from lobular carcinoma to emphasize the importance of gynecologic surveillance in breast cancer survivors and to identify areas that require further investigation.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
|
ER positive • HER-2 negative • BRCA mutation • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
Kisqali (ribociclib) • letrozole